HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT03870776

MAP4343 for Depression After Other Treatments Have Not Helped

About this titleRead the official source — NCT03870776
Medication studyAges 18–80France
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 80 years.

Listed locations
Angers and 9 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: June 1, 2019
Recruitment status
Completed
Enrollment listed in the registry
126
Sponsor
Mapreg
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
France
Age range
From 18 Years to 80 Years
Official registry ID
NCT03870776
Official title
Show the full official title

Double-blind,Controlled,Randomized Phase 2 Study of Efficacy,Safety,Pharmacokinetics& Pharmacodynamics of Daily Oral Administration of MAP4343 During 6 Weeks in Antidepressant Non-responders Patients Experiencing a Major Depressive Episode

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Angers · Besançon · Élancourt

6 more locations
  • La Roche-sur-Yon
  • Lille
  • Nantes
  • Paris
  • Poitiers
  • Tours
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Mapreg.

Did this study involve medication?

Yes. The study involved medication, including MAP4343 and Placebo.

Who was this study for?

Listed age limits: 18 years to 80 years.

Want to explore more studies?

Explore studies